Lantheus Reports Strong Q1 GAAP EPS Growth, Key FDA Approvals, Reaffirms Full-Year Guidance

summarizeSummary

Lantheus Holdings reported mixed first-quarter 2026 financial results with significant GAAP EPS growth and reaffirmed full-year guidance, alongside key FDA approvals for PYLARIFY TruVu and tentative approval for PNT2003.

check_boxKey Events

• Strong GAAP EPS Growth

  GAAP fully diluted earnings per share increased 76.5% to $1.80 in Q1 2026, compared to $1.02 in Q1 2025.

• Mixed Financial Performance

  Worldwide revenue increased 1.2% to $377.3 million, while adjusted fully diluted EPS decreased 4.6% to $1.46. Operating income also decreased by 20.3%.

• Key Product Sales Update

  Sales of PYLARIFY decreased 6.5% to $240.9 million, while Neuraceq sales were $35.4 million and DEFINITY sales increased 6.8% to $84.6 million.

• Significant Regulatory Approvals

  Received FDA approval for PYLARIFY TruVu, a new formulation for enhanced manufacturing, with a phased launch planned for Q4 2026. Also achieved FDA tentative approval for PNT2003, a potential first radioequivalent for GEP-NETs.

auto_awesomeAnalysis

Lantheus Holdings reported a mixed first quarter, with GAAP fully diluted earnings per share significantly increasing by 76.5% year-over-year, while adjusted fully diluted EPS saw a slight decrease. Revenue grew modestly by 1.2%. Despite a 6.5% decline in sales for its key product PYLARIFY and a decrease in operating income, the company achieved two significant regulatory milestones: FDA approval for PYLARIFY TruVu (a new formulation for manufacturing efficiency) and tentative FDA approval for PNT2003, which is expected to be the first radioequivalent for GEP-NETs. The reaffirmation of full-year 2026 revenue and adjusted EPS guidance, following the strategic pivot outlined in the recent 10-K, signals management's confidence in its pipeline and operational strategy despite some near-term product sales fluctuations. Investors should monitor the phased launch of PYLARIFY TruVu and the progress of PNT2003 towards full approval, as these represent significant future growth drivers.